# Pan Tumor Rollover Study

Source: https://onco.cc/trials/nct03899155/  
OnCo record `nct03899155` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Nivolumab, Ipilimumab, Cabozantinib, Trametinib, Capecitabine and Bevacizumab in advanced solid tumours, run by Bristol-Myers Squibb, now recruiting.

## Summary

Pan Tumor Rollover Study is a phase 2 interventional study registered as NCT03899155 by Bristol-Myers Squibb, with 1500 participants planned, started 2019-08-09 and due to reach its primary completion in 2029-08-25. Interventions recorded: Nivolumab, Ipilimumab, Cabozantinib, Trametinib, Relatlimab and Nivolumab + Relatlimab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03899155
- Phase: 2
- Setting: Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer Therapies
- Sponsor: Bristol-Myers Squibb
- Enrolled: 1500

## Sources

- ClinicalTrials.gov NCT03899155: https://clinicaltrials.gov/study/NCT03899155

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Cabozantinib](https://onco.cc/drugs/cabozantinib/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Trametinib](https://onco.cc/drugs/trametinib/)
- companies: [Advanced Accelerator Applications (Novartis)](https://onco.cc/companies/advanced-accelerator-applications/), [Bristol Myers Squibb](https://onco.cc/companies/bms/), [Clovis Oncology](https://onco.cc/companies/clovis-oncology/), [Exelixis](https://onco.cc/companies/exelixis/)

---
JSON: https://onco.cc/api/v1/entities/nct03899155.json